Your Cart ( 1 Item )
-
Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials
October 2019 | Volume 18 | Issue 10 | Original Article | 1012 | Copyright © October 2019Mark G. Lebwohl MD,ª Jeffrey L. Sugarman MD PhD,B Linda Stein Gold MD,c Tina Lin PharmD,d Robert Israel MDe
You will have 48 hours to download the full-text PDFPrice
24.95
Total ( 1 Item ) $24.95 CHECKOUT